Imfinzi combination snags FDA approval for high-risk non-muscle invasive bladder cancer

The FDA has approved an immunotherapy combination therapy for adult patients with Bacillus Calmette-Guérin-naive, high-risk non-muscle invasive bladder cancer.The combination of durvalumab (Imfinzi, AstraZeneca) plus Bacillus Calmette-Guérin (BCG) is the first of its kind to be approved for this patient population, according to a manufacturer-issued press release.